Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a

Charles River Laboratories International, Inc. (CRL) Book value per share

Alert me on Book value per share

Charles River Laboratories International, Inc.'s book value per share at the end of fiscal 2025 was 64.0×, down 5.22% from 67.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 67.6×. Over the past ten years it has ranged from 15.9× (fiscal 2015) to 70.3× (fiscal 2023); the current reading is higher than 82% of that period. Charles River Laboratories International, Inc. ranks 7th of 49 Diagnostics & Research companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 64.0× (5.22%)
FY2024 67.5× (4.04%)
FY2023 70.3× 19.86%
FY2022 58.7× 16.21%
FY2021 50.5× 18.10%
FY2020 42.7× 27.19%
FY2019 33.6× 22.10%
FY2018 27.5× 24.78%
FY2017 22.1× 23.59%
FY2016 17.8× 12.52%

Quarterly newest first

Period Book value per share Change
Sep 2026 67.6× 14.08%
Jun 2026 59.3× (1.54%)
Mar 2026 60.2× (5.89%)
Dec 2025 64.0× (7.71%)
43 more quarters

Against its own ten years

Low 15.9× High 70.3×
Ten-year median 42.7×
Current reading's percentile 82

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on CRL